KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Enterprise Value: 2009-2025

Historic Enterprise Value for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $833.1 million.

  • Neogenomics' Enterprise Value fell 44.55% to $833.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 123.99%. This contributed to the annual value of $1.7 billion for FY2024, which is 4.94% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Enterprise Value is $833.1 million, which was up 7.22% from $777.1 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Enterprise Value peaked at $5.4 billion during Q3 2021, and registered a low of $550.8 million during Q2 2022.
  • Its 3-year average for Enterprise Value is $1.4 billion, with a median of $1.5 billion in 2024.
  • As far as peak fluctuations go, Neogenomics' Enterprise Value plummeted by 88.42% in 2022, and later soared by 197.89% in 2023.
  • Quarterly analysis of 5 years shows Neogenomics' Enterprise Value stood at $3.7 billion in 2021, then tumbled by 80.22% to $729.1 million in 2022, then spiked by 125.94% to $1.6 billion in 2023, then rose by 4.94% to $1.7 billion in 2024, then slumped by 44.55% to $833.1 million in 2025.
  • Its Enterprise Value stands at $833.1 million for Q3 2025, versus $777.1 million for Q2 2025 and $861.0 million for Q1 2025.